| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Open Orphan secures £3m Covid-19 challenge study contract
StockMarketWire.com
|
Pharmaceutical services company Open Orphan had signed contract worth £3 million with Imperial College London to manufacture a SARS-CoV-2 challenge virus.
Challenge studies involve intentionally infecting individuals with a pathogen to test treatments or vaccines. SARS-CoV-2 is the virus that causes Covid-19.
Open Orphan's hVIVO unit would develop a new SARS-CoV-2 challenge virus based on new emerging variants of the virus.
The would be used in future hVIVO-run human challenge trials to allow direct comparisons of vaccines or antivirals against different Covid-19 variants.
The manufacturing project would begin immediately and was expected to complete before the end of 2021.
Following completion of the manufacturing project there is the potential for a follow on characterisation study, Open Orphan said.
Story provided by StockMarketWire.com
|
|
|
|
|
|
